Skip to Main Content

Opana ER will be removed from the marketplace

Opana ER will be voluntarily removed from the marketplace, per the announcement last week of manufacturer Endo International plc. This follows the FDA’s suggestion that we blogged about last month—and it is an important next step in the fight against opioid abuse.

No date has been set to remove the medication, but we’re closely monitoring the REDBOOK AWP price list for the Opana ER National Drug Code (NDC).

Simone Van Der Koelen 611419 Unsplash (1)

Immediate Effects on WCMSAs

The Centers for Medicare and Medicaid Services (CMS) policy and process won’t exclude the medication from Workers’ Compensation Medicare Set-Asides (WCMSAs) until the NDC code is officially deleted. If parties want to proactively calculate the cost of excluding Opana ER, we recommend holding off on CMS submission of the WCMSA until the NDC removal is complete.

Ideally, Endo’s announcement to remove Opana ER will influence prescribers to proactively switch their patients from Opana ER to a different and less expensive pain medication. That could allow parties to reduce the WCMSA amount before the Opana ER NDC is removed.

If you have questions about Opana ER or WCMSAs, please feel free to email Sid Wong at

Sid Wong, J.D.

Sid Wong is vice president of policy, Casualty Solutions at Verisk. You can contact Sid at

Visualize Subscribe

Get the best of Visualize!

We'll send Visualize Monthly, and our most popular content, right to your inbox.

Subscribe now

You will soon be redirected to the 3E website. If the page has not redirected, please visit the 3E site here. Please visit our newsroom to learn more about this agreement: Verisk Announces Sale of 3E Business to New Mountain Capital.